Payment & Shipping Terms:
|Other Name:||Finastid; Propecia; Finpecia; N - Tert - Butyl - 3 - Oxo - 4- Aza - 5α - Androst - 1- En -17β - Carboxamide; Finasteride; Proscar; MK 906||Payment Terms:||T/T, Western Union, Paypal, Moneygram|
|Trade Terms:||FOB CNF CIF DAP DDU||Shipping:||DHL TNT FedEx HKEMS UPS|
pharmaceutical raw materials
Finasteride Medicine Raw Material For prostatic hyperplasia male pattern hair loss 98319-26-7
Finasteride is a 4 - azotypic compound, which is a specific inhibitor of intracellular enzyme - II type 5a - reductase in the process of testosterone metabolism. Benign prostatic hyperplasia or prostatic hypertrophy depends on the conversion of testosterone into dihydrotestosterone in the prostate.
This drug can effectively reduce blood and dihydrotestosterone in the prostate gland. The androgen receptor has no affinity for the androgen receptor. Finasteride belong to 5 alpha reductase inhibitors, the mechanism is through its hormone, the inhibition of testosterone into dihydrotestosterone (DHT), increase the shrinkage and improve symptoms of prostate and urinary flow rate, prevention of benign prostatic hyperplasia ( BPH ).
This medication in a long - term efficacy and safety of ( PLESS ), in the study of symptoms of moderate to severe hyperplasia of prostate, 3016 prostate hyperplasia patients treated with this drug is 4 years relevant disposal ( surgical intervention ), urinary system such as transurethral resection of the prostate gland and other resection of the prostate, or need to insert the catheter acute urinary retention is evaluated.In this double - blind, randomized, placebo - controlled, multicenter study, treatment with this drug to the disposal of the overall risk of urinary system was reduced by 51%, with significant and sustained of prostate volume shrinking, and continuous maximum urinary flow rate increased and the symptoms improve.
Finasteride is 4 - nitrogen compounds of steroid hormones, for specific Ⅱ type 5 alpha reductase inhibitors, inhibition of peripheral testosterone into dihydrotestosterone ( DHT ), reduce blood and prostate, skin, etc in DHT levels in the organization.The growth and development of the prostate and benign hyperplasia depends on DHT, finasteride by lowering blood and DHT levels in the prostate tissue and suppress hyperplasia of prostate and improve the related clinical symptoms of benign prostatic hyperplasia.
Used to treat prostatic hyperplasia.
BPH patients with enlarged prostate and lower urinary tract symptoms.
Patients with higher prostate volume ( 40ml ) and / or serum PSA levels ( PSA than 1.4ng/ml ) had better results
|Test Items||Specification||Test Results|
|Description||White or off-white crystalline powder||Off-white crystalline powder|
|Identification||IR||Matches with working standard||Complies|
|Solubility||Freely soluble in chloroform and in alcohol;
Very slightly soluble in water
|Residue on ignition||≤0.1%||0.05%|
|Relative material||Maximum impurities≤0.5%||0.36%|
|Conclusion||The specification conform with Enterprise standard|